Age‐related changes in testosterone and the role of replacement therapy in older men
The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
Abstract
Western populations represent an ageing society with continuing gains being made in life expectancy; a male born in Australia has a healthy life expectancy of 70 years with slightly lower expectations for those born in the UK and USA (WHO, 2001). The search for ways to maintain and enhance physical health and well-being is endless. Rather than aiming to simply live longer, people aspire to undertake 'active ageing' (WHO, 2002), with an emphasis on quality of life. Attention has been focussed on the possibility that testosterone replacement therapy may be beneficial to the quality of life of men in middle age and beyond, akin to that of the role of oestrogen replacement for symptomatic peri- and postmenopausal women (Hlatky et al., 2002). Although the clinical presentation of androgen deficiency in men with primary or secondary testicular failure is well recognized and the benefits of treatment well established (Allan & McLachlan, 2003), whether testosterone replacement therapy is beneficial for older men with more subtle age-associated declines in serum testosterone levels is beneficial remains uncertain. Ill-defined terms such as 'andropause' or 'partial androgen deficiency of ageing men' have been popularized and underscore the increasing use of testosterone treatment for a range of ailments prevalent in older men. In the USA, the market for testosterone therapies has increased from US$49 million to almost US$400 million between 1997 and , with the majority of prescribing being for men 40 years and older. No matter how well-intentioned, such treatment cannot escape evaluation according to the modern principles of evidence-based medicine. Recent experiences in the field of female HRT (Hulley et al., 1998; Rossouw et al., 2002) serve to remind us of the need for properly designed and powered randomized, placebo-controlled data, and for caution in extrapolating cross-sectional or surrogate end-point data. We will discuss the extent of age-related decline in testosterone and the confounding effects of concomitant illness, the physiology of the changes in the hypothalamo–pituitary–testicular (HPT) axis, and the approaches to the laboratory assessment of hypoandrogenism in older men. The effects of androgens on key target tissues and the existing data from the limited number of placebo-controlled trials regarding the benefits and potential risks of its usage will be discussed. Unlike the predictable 90% fall in serum oestradiol across the menopause (Burger et al., 2002), testosterone levels in men begin to decline in the late third or early fourth decade and diminish at a constant rate thereafter (Baker et al., 1976b; Leifke et al., 2000; Harman et al., 2001). Many cross-sectional and several longitudinal studies have now documented significantly lower total testosterone levels in older men when compared to their younger counterparts (Feldman et al., 2002; Zumoff et al., 1982; Gray et al., 1991a, 1991b; Tenover & Bremner, 1991; Simon et al., 1992; Morley et al., 1997; Zmuda et al., 1997; Ferrini & Barrett-Connor, 1998; Harman et al., 2001). Those studies that have failed to identify this fall in testosterone have been criticized for the timing of sample collection (Harman & Tsitouras, 1980), the small numbers of subjects (Nankin & Calkins, 1986), or because of unexpectedly low testosterone levels in the younger subjects (Sparrow et al., 1980; Nieschlag et al., 1982). The absolute rate of decline in total testosterone levels in longitudinal studies varies threefold – from 0·11 nm (Harman et al., 2001) to 0·29 nm (Feldman et al., 2002) to 0·38 nm (Morley et al., 1997) per year. As a percentage of baseline values, cross-sectional studies estimate the rate of decline to be 0·5–0·8% per year (Davidson et al., 1983; Gray et al., 1991b; Simon et al., 1992), while longitudinal studies suggest a greater rate of decline, e.g. 1·6% per annum in the Massachusetts Male Ageing Study (MMAS; Feldman et al., 2002). Concomitant with the fall in total testosterone is a rise in SHBG levels with ageing (Field et al., 1994; Harman et al., 2001), estimated to be 1·3% per year in a cohort aged 40 years and over (Feldman et al., 2002). As a result of the combined effects of a rise in SHBG and a fall in total testosterone, calculated free testosterone levels decrease by approximately 2–3% per year (Feldman et al., 2002). The relationship between the changes in total testosterone and SHBG is unclear. Excluding obese men, in whom SHBG levels are reduced as a function of adiposity (Field et al., 1994), one group has described a fall in total testosterone from the age of 30 years with SHBG levels rising only from the age of 50 years (Leifke et al., 2000), whereas others have identified an earlier rise in SHBG with total testosterone levels falling only from the age of 55 years (Vermeulen et al., 1996). Ageing and obesity have opposing effects on SHBG levels. Given the increasing prevalence of obesity (Ball et al., 2002; 65% of Australian me
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hulley, S. (1998) · JAMA · doi:10.1001/jama.280.7.605 · Cited by 6,216
A Critical Evaluation of Simple Methods for the Estimation of Free Testosterone in Serum
Vermeulen, A., Verdonck, L., & Kaufman, J. M. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.84.10.6079 · Cited by 3,824 · cited 3×
“Calculations have been devised to determine the free component of testosterone based on the total levels of testosterone, SHBG and albumin, and make the reasonable assumption that the affinity constants for testosterone binding to both proteins are constant (Vermeulen et al ., 1999).”
BackgroundMethodInfluentialLongitudinal Effects of Aging on Serum Total and Free Testosterone Levels in Healthy Men
Harman, S. M., Metter, E. J., Tobin, J. D., Pearson, J., & Blackman, M. R. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.2.7219 · Cited by 2,760
Feldman, H. A., Longcope, C., Derby, C. A., Johannes, C. B., Araujo, A. B., Coviello, A. D., Bremner, W. J., & McKinlay, J. B. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.2.8201 · Cited by 1,861
Södergard, R., Bäckström, T., Shanbhag, V., & Carstensen, H. (1982) · Journal of Steroid Biochemistry · doi:10.1016/0022-4731(82)90038-3 · Cited by 1,080
Testosterone dose-response relationships in healthy young men
Bhasin, S., Woodhouse, L., Casaburi, R., Singh, A. B., Bhasin, D., Berman, N., Chen, X., Yarasheski, K. E., Magliano, L., Dzekov, C., et al. (2001) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.2001.281.6.e1172 · Cited by 967 · cited 1×
“In younger men increments in LBM and decrements in fat mass are directly proportional to the dose of testosterone administered (Bhasin et al., 2001).”
BackgroundMorley, J. E., Kaiser, F. E., Perry, H. M., Patrick, P., Morley, P. M. K., Stauber, P. M., Vellas, B., Baumgartner, R. N., & Garry, P. J. (1997) · Metabolism · doi:10.1016/s0026-0495(97)90057-3 · Cited by 830
Loss of Circadian Rhythmicity in Blood Testosterone Levels with Aging in Normal Men*
Bremner, W. J., Vitiello, M. V., & Prinz, P. N. (1983) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-56-6-1278 · Cited by 785 · cited 2×
“This diurnal pattern may be attenuated as a function of ageing (Bremner et al ., 1983; Gupta et al ., 2000) but as the loss is not universal (Diver et al ., 2003), testosterone levels should be taken in the morning.”
BackgroundEffects of testosterone supplementation in the aging male
Tenover, J. S. (1992) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.75.4.1092 · Cited by 768
Falahati-Nini, A., Riggs, B. L., Atkinson, E. J., O’Fallon, W. M., Eastell, R., & Khosla, S. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10942 · Cited by 757 · cited 1×
“In older men subjected to independent withdrawal of oestrogen and testosterone, oestrogen prevented an increase in bone resorption markers whilst both hormones played a role in bone formation (Falahati-Nini et al., 2000).”
Background
Cited by
Wu, F. C. W., Tajar, A., Pye, S. R., Silman, A. J., Finn, J. D., O'Neill, T. W., Bartfai, G., Casanueva, F., Forti, G., Giwercman, A., et al. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-1972 · Cited by 939
Anabolic Deficiency in Men With Chronic Heart Failure: Prevalence and Detrimental Impact on Survival
Jankowska, E. A., Biel, B., Majda, J., Szklarska, A., Lopuszanska, M., Medras, M., Anker, S. D., Banasiak, W., Poole-Wilson, P. A., & Ponikowski, P. (2006) · Circulation · doi:10.1161/circulationaha.106.649426 · Cited by 377
The benefits and risks of testosterone replacement therapy: a review
Morley, J. (2009) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s3025 · Cited by 369
Allan, C. A., Strauss, B. J. G., Burger, H. G., Forbes, E. A., & McLachlan, R. I. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-1291 · Cited by 298
Self-citationTracz, M. J., Sideras, K., Boloña, E. R., Haddad, R. M., Kennedy, C. C., Uraga, M. V., Caples, S. M., Erwin, P. J., & Montori, V. M. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0036 · Cited by 275
Acute Effects of Sex Steroid Hormones on Susceptibility to Cardiac Arrhythmias: A Simulation Study
Yang, P.-C., Kurokawa, J., Furukawa, T., & Clancy, C. E. (2010) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1000658 · Cited by 75
“of testosterone begin to decline in men as young as 40 [22].”
BackgroundLi, C. Y., Basit, A., Gupta, A., Gáborik, Z., Kis, E., & Prasad, B. (2019) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2019.03.027 · Cited by 73
“People with low T levels experience fatigue, depression, low sex drive, loss of muscle mass, diabetes, obesity, cardiovascular diseases, or osteoporosis [2].”
BackgroundManagement of side effects of androgen deprivation therapy
Grossmann, M., & Zajac, J. D. (2011) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2011.05.004 · Cited by 69
Body composition, metabolic syndrome and testosterone in ageing men
Allan, C. A., Strauss, B. J. G., & McLachlan, R. I. (2007) · International Journal of Impotence Research · doi:10.1038/sj.ijir.3901552 · Cited by 67
Self-citationSarkar, M., VanWagner, L. B., Terry, J. G., Carr, J. J., Rinella, M., Schreiner, P. J., Lewis, C. E., Terrault, N., & Cohort, F. T. C. A. R. D. I. Y. A. (. (2019) · American Journal of Gastroenterology · doi:10.14309/ajg.0000000000000138 · Cited by 37
Metadata
- Authors
- Allan, C. A., & McLachlan, R. I.
- Venue
- Clinical Endocrinology
- Publisher
- Wiley
- Published
- 2004-04-08
- Volume
- 60
- Issue
- 6
- Pages
- 653-670
- ISSN
- 0300-0664 (ISSN-L)
- 1365-2265
- OpenAlex
- W1981476069
- Cited by
- 128
- References
- 56
- FWCI
- 3.82
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.